Download PDF
Semin Neurol 2009; 29(4): 354-367
DOI: 10.1055/s-0029-1237114
© Thieme Medical Publishers

Primary Hypersomnias of Central Origin

Eric Frenette1 , Clete A. Kushida1
  • 1Stanford Sleep Clinic, Stanford, California
Further Information

Publication History

Publication Date:
09 September 2009 (online)

    Permissions and Reprints

ABSTRACT

Hypersomnia is a frequently encountered symptom in clinical practice. The cardinal manifestation is inappropriate daytime sleepiness, common to all types of hypersomnias. Hypersomnias of central origin are a rare cause of excessive daytime sleepiness, much rarer than the hypersomnia related to other pathologies, such as sleep-disordered breathing. Narcolepsy, with or without cataplexy, remains the most well studied of the primary hypersomnias. Although recognized more than a century ago, it was not until the end of the 20th century that major breakthroughs led to a better understanding of the disease, with hope of more specific therapies. The authors review the major aspects of this disorder, including the newer treatment modalities. Idiopathic hypersomnia is also part of the primary hypersomnias. Although difficult to diagnose, certain peculiarities stand out to help us differentiate it from the more commonly seen narcolepsy. The recurrent hypersomnias, particularly the Kleine–Levin syndrome, will be discussed. This rare disorder has been studied more closely in the last few years with abundant epidemiologic data assembled through literature and worldwide case reviews. Understanding the primary central hypersomnias warrants a thorough look from the original description, as well as a peek at the future, while more efficacious diagnostic and therapeutic interventions are currently being developed.

KEYWORDS

Primary hypersomnia - narcolepsy - cataplexy - idiopathic hypersomnia - Kleine–Levin syndrome

REFERENCES

  • 1 Schenck C H, Bassetti C L, Arnulf I, Mignot E. English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th century, with commentary.  J Clin Sleep Med. 2007;  3(3) 301-311
    PubMedGoogle Scholar
  • 2 Adie W J. Idiopathic narcolepsy: a disease sui generis; with remarks on the mechanism of sleep.  Brain. 1926;  49 257-306
    CrossrefPubMedGoogle Scholar
  • 3 Prinzmetal M, Bloomberg W. The use of Benzedrine for the treatment of narcolepsy.  JAMA. 1935;  105 2051-2054
    PubMedGoogle Scholar
  • 4 Billiard M, Besset A, Montplaisir J et al.. Modafinil: a double-blind multicentric study.  Sleep. 1994;  17(8, Suppl) S107-S112
    PubMedGoogle Scholar
  • 5 Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy.  Dis Nerv Syst. 1960;  21 704-706
    PubMedGoogle Scholar
  • 6 Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate.  Can J Neurol Sci. 1979;  6(1) 1-6
    PubMedGoogle Scholar
  • 7 U.S. Xyrem Multicenter Study Group . A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.  Sleep. 2002;  25(1) 42-49
    CrossrefPubMedGoogle Scholar
  • 8 Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.  Tissue Antigens. 1984;  24(5) 316-319
    CrossrefPubMedGoogle Scholar
  • 9 Mignot E, Lin X, Arrigoni J et al.. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans.  Sleep. 1994;  17(8, Suppl) S60-S67
    PubMedGoogle Scholar
  • 10 de Lecea L, Kilduff T S, Peyron C et al.. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.  Proc Natl Acad Sci U S A. 1998;  95(1) 322-327
    CrossrefPubMedGoogle Scholar
  • 11 Nishino S, Ripley B, Overeem S, Lammers G J, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy.  Lancet. 2000;  355(9197) 39-40
    CrossrefPubMedGoogle Scholar
  • 12 Peyron C, Faraco J, Rogers W et al.. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.  Nat Med. 2000;  6(9) 991-997
    CrossrefPubMedGoogle Scholar
  • 13 Thannickal T C, Moore R Y, Nienhuis R et al.. Reduced number of hypocretin neurons in human narcolepsy.  Neuron. 2000;  27(3) 469-474
    CrossrefPubMedGoogle Scholar
  • 14 Yoss R E, Daly D D. Treatment of narcolepsy with ritalin.  Neurology. 1959;  9(3) 171-173
    PubMedGoogle Scholar
  • 15 Vogel G. Studies in psychophysiology of dreams. III. The dream of narcolepsy.  Arch Gen Psychiatry. 1960;  3 421-428
    PubMedGoogle Scholar
  • 16 Xyrem approved for muscle problems in narcolepsy.  FDA Consum. 2002;  36(5) 7
    PubMedGoogle Scholar
  • 17 Ohayon M M, Priest R G, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population.  Neurology. 2002;  58(12) 1826-1833
    CrossrefPubMedGoogle Scholar
  • 18 Silber M H, Krahn L E, Olson E J, Pankratz V S. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study.  Sleep. 2002;  25(2) 197-202
    PubMedGoogle Scholar
  • 19 Dauvilliers Y, Montplaisir J, Molinari N et al.. Age at onset of narcolepsy in two large populations of patients in France and Quebec.  Neurology. 2001;  57(11) 2029-2033
    PubMedGoogle Scholar
  • 20 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50(2, Suppl 1) S16-S22
    CrossrefPubMedGoogle Scholar
  • 21 Guilleminault C, Dement WC, Passouant P Narcolepsy. New York; Spectrum Publications 1976
    Google Scholar
  • 22 Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy.  Clin Neurophysiol. 2003;  114(11) 2000-2017
    CrossrefPubMedGoogle Scholar
  • 23 Bassetti CL, Billiard M, Mignot E Narcolepsy and Hypersomnia. Lung Biology in Health and Disease. Vol. 220. New York; Informa Healthcare 2007
    Google Scholar
  • 24 Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis.  Adv Neurol. 1995;  67 245-271
    PubMedGoogle Scholar
  • 25 Takeuchi T, Miyasita A, Inugami M, Sasaki Y, Fukuda K. Laboratory documented hallucination during sleep-onset REM period in a normal subject.  Percept Mot Skills. 1994;  78(3 Pt 1) 979-985
    PubMedGoogle Scholar
  • 26 Szucs A, Janszky J, Holló A, Migléczi G, Halász P. Misleading hallucinations in unrecognized narcolepsy.  Acta Psychiatr Scand. 2003;  108(4) 314-316, 316–317
    CrossrefPubMedGoogle Scholar
  • 27 Plazzi G, Serra L, Ferri R. Nocturnal aspects of narcolepsy with cataplexy.  Sleep Med Rev. 2008;  12(2) 109-128
    CrossrefPubMedGoogle Scholar
  • 28 Sturzenegger C, Bassetti C L. The clinical spectrum of narcolepsy with cataplexy: a reappraisal.  J Sleep Res. 2004;  13(4) 395-406
    CrossrefPubMedGoogle Scholar
  • 29 Aldrich M S. Diagnostic aspects of narcolepsy.  Neurology. 1998;  50(2, Suppl 1) S2-S7
    PubMedGoogle Scholar
  • 30 Dauvilliers Y, Pennestri M H, Petit D, Dang-Vu T, Lavigne G, Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy.  J Sleep Res. 2007;  16(3) 333-339
    CrossrefPubMedGoogle Scholar
  • 31 Nightingale S, Orgill J C, Ebrahim I O, de Lacy S F, Agrawal S, Williams A J. The association between narcolepsy and REM behavior disorder (RBD).  Sleep Med. 2005;  6(3) 253-258
    CrossrefPubMedGoogle Scholar
  • 32 Dauvilliers Y, Rompré S, Gagnon J F, Vendette M, Petit D, Montplaisir J. REM sleep characteristics in narcolepsy and REM sleep behavior disorder.  Sleep. 2007;  30(7) 844-849
    PubMedGoogle Scholar
  • 33 Baker T L, Guilleminault C, Nino-Murcia G, Dement W C. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia.  Sleep. 1986;  9(1 Pt 2) 232-242
    PubMedGoogle Scholar
  • 34 Mignot E, Hayduk R, Black J, Grumet F C, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.  Sleep. 1997;  20(11) 1012-1020
    PubMedGoogle Scholar
  • 35 Nishino S. The hypothalamic peptidergic system, hypocretin/orexin and vigilance control.  Neuropeptides. 2007;  41(3) 117-133
    CrossrefPubMedGoogle Scholar
  • 36 Guilleminault C, Gelb M. Clinical aspects and features of cataplexy.  Adv Neurol. 1995;  67 65-77
    PubMedGoogle Scholar
  • 37 Rubboli G, d'Orsi G, Zaniboni A et al.. A video-polygraphic analysis of the cataplectic attack.  Clin Neurophysiol. 2000;  111(Suppl 2) S120-S128
    CrossrefPubMedGoogle Scholar
  • 38 Overeem S, Reijntjes R, Huyser W, Lammers G J, van Dijk J G. Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia.  J Sleep Res. 2004;  13(3) 257-264
    CrossrefPubMedGoogle Scholar
  • 39 Overeem S, Lammers G J, van Dijk J G. Cataplexy: ‘tonic immobility’ rather than ‘REM-sleep atonia’?.  Sleep Med. 2002;  3(6) 471-477
    PubMedGoogle Scholar
  • 40 Johns M W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.  Sleep. 1991;  14(6) 540-545
    Google Scholar
  • 41 Richardson G S, Carskadon M A, Flagg W, Van den Hoed J, Dement W C, Mitler M M. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects.  Electroencephalogr Clin Neurophysiol. 1978;  45(5) 621-627
    PubMedGoogle Scholar
  • 42 Littner M R, Kushida C, Wise M Standards of Practice Committee of the American Academy of Sleep Medicine et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test.  Sleep. 2005;  28(1) 113-121
    PubMedGoogle Scholar
  • 43 Mignot E, Lammers G J, Ripley B et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.  Arch Neurol. 2002;  59(10) 1553-1562
    CrossrefPubMedGoogle Scholar
  • 44 American Sleep Disorders Association, Diagnostic Classification Steering Committee .International Classification of Sleep Disorders: Diagnostic and Coding Manual, ICSD-R. Westchester, IL; American Academy of Sleep Medicine 2005
    PubMedGoogle Scholar
  • 45 U.S. Food and Drug Administration (FDA) .InfoSheets. 2005. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/pemolineHCP.pdf Accessed September 20, 2008
    PubMedGoogle Scholar
  • 46 Mitler M M, Hajdukovic R, Erman M K. Treatment of narcolepsy with methamphetamine.  Sleep. 1993;  16(4) 306-317
    PubMedGoogle Scholar
  • 47 Kuczenski R, Segal D S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine.  J Neurochem. 1997;  68(5) 2032-2037 , Erratum in: J Neurochem 1997;69(3):1332
    PubMedGoogle Scholar
  • 48 Mitler M M, Shafor R, Hajdukovich R, Timms R M, Browman C P. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline.  Sleep. 1986;  9(1 Pt 2) 260-264
    PubMedGoogle Scholar
  • 49 Wisor J P, Nishino S, Sora I, Uhl G H, Mignot E, Edgar D M. Dopaminergic role in stimulant-induced wakefulness.  J Neurosci. 2001;  21(5) 1787-1794
    PubMedGoogle Scholar
  • 50 Qu W M, Huang Z L, Xu X H, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil.  J Neurosci. 2008;  28(34) 8462-8469
    CrossrefPubMedGoogle Scholar
  • 51 Wisor J P, Eriksson K S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil.  Neuroscience. 2005;  132(4) 1027-1034
    CrossrefPubMedGoogle Scholar
  • 52 Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group.  Ann Neurol. 1998;  43(1) 88-97
    CrossrefPubMedGoogle Scholar
  • 53 Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group.  Neurology. 2000;  54(5) 1166-1175
    CrossrefPubMedGoogle Scholar
  • 54 Moldofsky H, Broughton R J, Hill J D. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy.  Sleep Med. 2000;  1(2) 109-116
    PubMedGoogle Scholar
  • 55 Xyrem International Study Group . Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients.  Sleep Med. 2005;  6(5) 415-421
    PubMedGoogle Scholar
  • 56 A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.  Sleep. 2003;  26(1) 31-35
    PubMedGoogle Scholar
  • 57 Black J, Houghton W C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.  Sleep. 2006;  29(7) 939-946
    PubMedGoogle Scholar
  • 58 Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy.  Sleep. 2004;  27(7) 1327-1334
    CrossrefPubMedGoogle Scholar
  • 59 Van Cauter E, Plat L, Scharf M B et al.. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men.  J Clin Invest. 1997;  100(3) 745-753
    CrossrefPubMedGoogle Scholar
  • 60 Schmidt H S, Clark R W, Hyman P R. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia.  Am J Psychiatry. 1977;  134(2) 183-185
    PubMedGoogle Scholar
  • 61 Schachter M, Parkes J D. Fluvoxamine and clomipramine in the treatment of cataplexy.  J Neurol Neurosurg Psychiatry. 1980;  43(2) 171-174
    CrossrefPubMedGoogle Scholar
  • 62 Vignatelli L, D'Alessandro R, Candelise L. Antidepressant drugs for narcolepsy.  Cochrane Database Syst Rev. 2008;  (1) CD003724
    PubMedGoogle Scholar
  • 63 Morgenthaler T I, Kapur V K, Brown T Standards of Practice Committee of the American Academy of Sleep Medicine et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.  Sleep. 2007;  30(12) 1705-1711
    PubMedGoogle Scholar
  • 64 Harsh J R, Hayduk R, Rosenberg R et al.. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.  Curr Med Res Opin. 2006;  22(4) 761-774
    CrossrefPubMedGoogle Scholar
  • 65 Lin J S. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons.  Sleep Med Rev. 2000;  4(5) 471-503
    CrossrefPubMedGoogle Scholar
  • 66 Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog.  Sleep. 2003;  26(8) 953-959
    PubMedGoogle Scholar
  • 67 Hanson L R, Martinez P M, Taheri S et al.. Intranasal administration of hypocretin-1 (orexin A) bypasses the blood-brain barrier and targets the brain:a new strategy for the treatment of narcolepsy.  Drug Delivery Technol. 2004;  4 66-71
    PubMedGoogle Scholar
  • 68 Arias-Carrión O, Murillo-Rodriguez E, Xu M, Blanco-Centurion C, Drucker-Colín R, Shiromani P J. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results.  Sleep. 2004;  27(8) 1465-1470
    PubMedGoogle Scholar
  • 69 Arias-Carrión O, Drucker-Colín R, Murillo-Rodríguez E. Survival rates through time of hypocretin grafted neurons within their projection site.  Neurosci Lett. 2006;  404(1-2) 93-97
    CrossrefPubMedGoogle Scholar
  • 70 Mieda M, Willie J T, Hara J, Sinton C M, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.  Proc Natl Acad Sci U S A. 2004;  101(13) 4649-4654
    CrossrefPubMedGoogle Scholar
  • 71 Hecht M, Lin L, Kushida C A et al.. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy.  Sleep. 2003;  26(7) 809-810
    PubMedGoogle Scholar
  • 72 Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis.  Ann Neurol. 2005;  58(3) 489-490
    CrossrefPubMedGoogle Scholar
  • 73 Lecendreux M, Maret S, Bassetti C, Mouren M C, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy.  J Sleep Res. 2003;  12(4) 347-348
    CrossrefPubMedGoogle Scholar
  • 74 Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.  Ann Neurol. 2004;  56(6) 905-908
    CrossrefPubMedGoogle Scholar
  • 75 Zuberi S M, Mignot E, Ling L et al.. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy.  J Sleep Res. 2004;  13(Suppl 1) 828
    PubMedGoogle Scholar
  • 76 Fronczek R, Verschuuren J, Lammers G J. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy.  J Neurol. 2007;  254(11) 1607-1608
    CrossrefPubMedGoogle Scholar
  • 77 Valko P O, Khatami R, Baumann C R, Bassetti C L. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy.  J Neurol. 2008;  255(12) 1900-1903
    CrossrefPubMedGoogle Scholar
  • 78 Fronczek R, Overeem S, Lammers G J, van Dijk J G, Van Someren E J. Altered skin-temperature regulation in narcolepsy relates to sleep propensity.  Sleep. 2006;  29(11) 1444-1449
    PubMedGoogle Scholar
  • 79 Fronczek R, Raymann R JEM, Romeijn N et al.. Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy.  Sleep. 2008;  31(2) 233-240
    PubMedGoogle Scholar
  • 80 Roth B, Nevsimalova S, Rechtschaffen A. Hypersomnia with “sleep drunkenness”.  Arch Gen Psychiatry. 1972;  26(5) 456-462
    PubMedGoogle Scholar
  • 81 Aldrich M S. The clinical spectrum of narcolepsy and idiopathic hypersomnia.  Neurology. 1996;  46(2) 393-401
    PubMedGoogle Scholar
  • 82 Bassetti C, Aldrich M S. Idiopathic hypersomnia. A series of 42 patients.  Brain. 1997;  120(Pt 8) 1423-1435
    CrossrefPubMedGoogle Scholar
  • 83 Billiard M, Dauvilliers Y. Idiopathic hypersomnia.  Sleep Med Rev. 2001;  5(5) 349-358
    CrossrefPubMedGoogle Scholar
  • 84 Anderson K N, Pilsworth S, Sharples L D, Smith I E, Shneerson J M. Idiopathic hypersomnia: a study of 77 cases.  Sleep. 2007;  30(10) 1274-1281
    PubMedGoogle Scholar
  • 85 Heier M S, Evsiukova T, Vilming S, Gjerstad M D, Schrader H, Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway.  Sleep. 2007;  30(8) 969-973
    PubMedGoogle Scholar
  • 86 Bové A, Culebras A, Moore J T, Westlake R E. Relationship between sleep spindles and hypersomnia.  Sleep. 1994;  17(5) 449-455
    PubMedGoogle Scholar
  • 87 Sforza E, Gaudreau H, Petit D, Montplaisir J. Homeostatic sleep regulation in patients with idiopathic hypersomnia.  Clin Neurophysiol. 2000;  111(2) 277-282
    CrossrefPubMedGoogle Scholar
  • 88 Nevsímalová S, Blazejová K, Illnerová H et al.. A contribution to pathophysiology of idiopathic hypersomnia.  Suppl Clin Neurophysiol. 2000;  53 366-370
    PubMedGoogle Scholar
  • 89 Bruck D, Parkes J D. A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data.  J Neurol Neurosurg Psychiatry. 1996;  60(5) 576-578
    CrossrefPubMedGoogle Scholar
  • 90 Montplaisir J, Fantini L. Idiopathic hypersomnia: a diagnostic dilemma. A commentary of “Idiopathic Hypersomnia” (M. Billiard and Y. Dauvilliers).  Sleep Med Rev. 2001;  5(5) 361-362
    CrossrefPubMedGoogle Scholar
  • 91 Critchley M, Hoffman H. The syndrome of periodic somnolence and morbid hunger (Kleine–Levin syndrome).  BMJ. 1942;  1 137-139
    CrossrefPubMedGoogle Scholar
  • 92 Arnulf I, Zeitzer J M, File J, Farber N, Mignot E. KleineLevin syndrome: a systematic review of 186 cases in the literature.  Brain. 2005;  128(Pt 12) 2763-2776
    CrossrefPubMedGoogle Scholar
  • 93 Arnulf I, Lin L, Gadoth N et al.. Kleine-Levin syndrome: a systematic study of 108 patients.  Ann Neurol. 2008;  63(4) 482-493
    CrossrefPubMedGoogle Scholar
  • 94 Huang Y S, Lin Y H, Guilleminault C. Polysomnography in KleineLevin syndrome.  Neurology. 2008;  70(10) 795-801
    CrossrefPubMedGoogle Scholar
  • 95 Gadoth N, Kesler A, Vainstein G, Peled R, Lavie P. Clinical and polysomnographic characteristics of 34 patients with KleineLevin syndrome.  J Sleep Res. 2001;  10(4) 337-341
    CrossrefPubMedGoogle Scholar
  • 96 Dauvilliers Y, Mayer G, Lecendreux M et al.. Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses.  Neurology. 2002;  59(11) 1739-1745
    PubMedGoogle Scholar
  • 97 Huang Y S, Guilleminault C, Kao P F, Liu F Y. SPECT findings in the Kleine-Levin syndrome.  Sleep. 2005;  28(8) 955-960
    PubMedGoogle Scholar
  • 98 Podestá C, Ferreras M, Mozzi M, Bassetti C, Dauvilliers Y, Billiard M. Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements.  Sleep Med. 2006;  7(8) 649-651
    PubMedGoogle Scholar
  • 99 Carpenter S, Yassa R, Ochs R. A pathologic basis for Kleine-Levin syndrome.  Arch Neurol. 1982;  39(1) 25-28
    PubMedGoogle Scholar
  • 100 Koerber R K, Torkelson R, Haven G, Donaldson J, Cohen S M, Case M. Increased cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in Kleine-Levin syndrome.  Neurology. 1984;  34(12) 1597-1600
    PubMedGoogle Scholar
  • 101 Muratori F, Bertini N, Masi G. Efficacy of lithium treatment in Kleine-Levin syndrome.  Eur Psychiatry. 2002;  17(4) 232-233
    CrossrefPubMedGoogle Scholar
  • 102 Surges R, Walker M C. A case of late-onset Kleine-Levin syndrome responding to lamotrigine.  Sleep Med. 2009;  10(3) 394
    PubMedGoogle Scholar
  • 103 Crumley F E. Valproic acid for Kleine-Levin syndrome.  J Am Acad Child Adolesc Psychiatry. 1997;  36(7) 868-869
    PubMedGoogle Scholar
  • 104 Kryger MH, Roth T, Dement WC Principles and Practice of Sleep Medicine. 4th ed. Amsterdam; Elsevier Available at: http://www.sleepmedtext.com/content/default.cfm Accessed November 12, 2008
    Google Scholar

Eric FrenetteM.D. F.R.C.P.(C) 

University of Sherbrooke Medical Center

3001 12th Avenue North, Sherbrooke, QC, Canada J1H 5N4

Email: eric.california@gmail.com

      >